Premium
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
Author(s) -
Hosseini Arezoo,
Gharibi Tohid,
Marofi Faroogh,
Javadian Mahsa,
Babaloo Zohreh,
Baradaran Behzad
Publication year - 2020
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.29593
Subject(s) - janus kinase , tofacitinib , rheumatoid arthritis , stat protein , stat , jak stat signaling pathway , medicine , cancer research , ruxolitinib , immunology , immune system , kinase , signal transduction , receptor , stat3 , biology , cytokine , tyrosine kinase , genetics , bone marrow , myelofibrosis
Many cytokines are crucial drivers of cancers and autoimmune conditions. These proteins bind to receptors and signal their responses through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. Genetic variations in the JAK–STAT pathway are correlated with the increased risk of cancers, autoimmunity as well as inflammatory diseases. Targeting JAKs and STATs can be a safe and efficacious strategy for treating these diseases. Tofacitinib, as the first JAK inhibitor, is approved for rheumatoid arthritis therapy. Also, many other JAK inhibitors have been proven or are in various phases of clinical trials for various diseases. At present, small‐molecule JAK inhibitors are considered as a novel category of drugs in the treatment of cancer and immune‐mediated diseases.